Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fluad Adjuvant Could Come Under Fire At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.


Related Content

CSL's Fluad Seems Headed For Post-Marketing Safety Study
Recent And Upcoming FDA Advisory Committee Meetings
Novartis Flu Vaccine Nightmare Ends; Worries Over Pharmacovigilance Overreaction Remain
Novartis Flu Vaccine Problems Highlight Lack Of European Co-ordination
Novartis Hopes To Avoid Long FDA Delay For MF59 Adjuvant in Flu Vaccine
Accelerated Approval Gives Wings To Pandemic Flu Vaccine Development


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts